Clinical Trials
9 trialsNCT07430202 2026-05-06
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Not yet recruiting
NCT07227012 2026-04-20
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Pfizer
Phase 1/2 Recruiting
NCT06362369 2026-04-13
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Phase 1/2 Recruiting
NCT03058289 2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2 Completed
NCT04340193 2024-11-26
CheckMate 74W
Bristol-Myers Squibb
Phase 3 Completed
NCT06492408 2024-07-09
Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT03752398 2024-07-05
DUET-3
Xencor, Inc.
Phase 1 Completed
NCT04311710 2023-02-24
CheckMate 76U
Bristol-Myers Squibb
Phase 1 Terminated
NCT02239900 2020-11-30
Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Completed